Loop Energy and Fraunhofer ISE Testing Demonstrates the Potential of Innovative eFlow™ Flow Field Design to Increase Hydrogen Production in Electrolyzers
6.3.2023 14:30:00 EET | Business Wire | Press release
Loop Energy ™ (TSX: LPEN), a designer and manufacturer of hydrogen fuel cell solutions, has completed third-party validation of the use of its patented eFlow™ technology in PEM electrolyzers. In partnership with Fraunhofer USA, testing was conducted by the German Fraunhofer Institute for Solar Energy Systems ISE, and has demonstrated a fuel cell architecture with trapezoid flow field design can enhance temperature uniformity. When incorporated into conventional PEM electrolysis cells, this bipolar plate architecture demonstrates it can increase hydrogen production. Loop Energy is now seeking industry partners to develop a full-scale electrolyzer prototype for commercial validation.
Results show that eFlow architecture creates a more stable and uniform operating environment in the PEM water electrolysis test cells compared to conventional flow fields with parallel channels, resulting in greater hydrogen production and improved efficiency. Testing also shows the enhanced uniform operating environment should have a beneficial impact on durability.
“Results from the validation process show that the new flow field technology has the potential to surpass typical levels of hydrogen production that we see in the industry today and supports green hydrogen production to become increasingly economically viable,” said Fraunhofer ISE Head of Department Chemical Energy Storage, Dr. Tom Smolinka. “The difference we have seen from current electrolyzer performance with conventional parallel flow field is that the adapted design appears to create more uniform temperature distribution could make it an enabling technology for some of the advanced materials needed to really increase the economics of electrolyzers and green hydrogen.”
Encouraged by the results, Loop Energy and Fraunhofer ISE are inviting expressions of interest from potential industry partners. Interested parties will partner with the two companies in designing and manufacturing an electrolyzer prototype to verify eFlow’s benefits for producing hydrogen on a commercial scale. All expressions of interest can be directed to Loop Energy Chief Commercial Officer, George Rubin.
“The completion of third-party validation is an important milestone for Loop Energy as we explore how eFlow can transform the hydrogen production sector,” said Loop Energy President & CEO, Ben Nyland. “We’re extremely pleased to partner with Fraunhofer ISE and draw on their long-lasting experience in cell and stack design for PEM water electrolysis. The results have been encouraging, and we’re excited to begin the search for strategic partners to support us as we innovate electrolyzer technology.”
Currently, Loop Energy’s proprietary eFlow technology is applied in its fuel cell products to offer unmatched levels of fuel efficiency. Its tapering channel design enables eFlow to provide improved uniform current density and increases gas velocity to deliver superior thermal and water management. With the new discovery that eFlow can benefit hydrogen production efficiency, it expands the patented technology’s potential use across the hydrogen energy vertical.
Global demand for hydrogen production is projected to grow by more than US$1 trillion by 20501. As a result, both new and existing hydrogen producers are searching for a competitive advantage to meet rising demand.
Ben Nyland will share details of this development at CERAWeek on March 6 and 7 alongside Thomas Schuelke, president of Fraunhofer USA, which also acts as project partner. In addition, Dr. Tom Smolinka and Loop Energy Chief Scientist, Dr. Sean Mackinnon will present the technical results at Hannover Messe on April 17. Requests for meetings at either event can be coordinated with Ethan Hugh.
Loop Energy’s management team will share more details on its end of year financial results call on March 30. Call details can be found on Loop Energy’s website.
About Fraunhofer ISE
The Fraunhofer-Gesellschaft, based in Germany, is the world's leading organization for application-oriented research. With its focus on key technologies of relevance to the future and on the exploitation of results in business and industry, it plays a central role in the innovation process. As a guide and stimulus for innovative developments and scientific excellence, it helps shape our society and our future. Founded in 1949, the organization currently operates 76 institutes and research facilities in Germany. More than 30,000 employees, most of them trained in the natural sciences or engineering, produce the annual research volume of 2.9 billion euros. Of this, 2.5 billion euros is spent on contract research. Further information: www.ise.fraunhofer.de/en
About Fraunhofer USA
Fraunhofer USA, Inc., a legally independent US affiliate founded by Fraunhofer-Gesellschaft, is an R&D organization working with industry, universities, and state and federal governments on contract R&D projects. Fraunhofer is in the high-tech problem-solving business and utilizes world class scientific and engineering expertise to engage in complex R&D projects across many different disciplines. Through Fraunhofer USA, U.S. clients can connect to the 79 research units throughout the U.S. and Germany with over 30,000 employees, predominantly scientists and engineers. www.fraunhofer.org
About Loop Energy Inc.
Loop Energy is a leading designer and manufacturer of hydrogen fuel cell systems targeted for the electrification of commercial vehicles, including light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop Energy’s products feature the company’s proprietary eFlow™ technology in the fuel cell stack’s bipolar plates. eFlow is designed to enable commercial customers to achieve performance maximization and cost minimization. Loop Energy works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop Energy is driving towards a zero-emissions future, visit www.loopenergy.com.
Forward Looking Warning
This press release contains forward-looking information within the meaning of applicable securities legislation, which reflect management’s current expectations and projections regarding future events. Particularly, statements regarding the Company’s expectations of future results, performance, achievements, prospects or opportunities or the markets in which we operate is forward-looking information, including without limitation, purchase orders, cost reduction, profitability and revenue targets; our future growth prospects and business outlook including without limitation the expected demand for our products, the allocation of resources and funds, the expected timeline for profitability, the planned growth of our customer base and the expected growth of our operations globally. Forward-looking information is based on a number of assumptions (including without limitation assumptions with respect the current and future performance of the Company’s products, growth in demand for the Company’s products, the Company’s ability to execute on its strategy, achieve its targets and progress existing and future customers through the Customer Adoption Cycle in a timely way, and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control and could cause actual results and events to vary materially from those that are disclosed, or implied, by such forward-looking information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005095/en/
Contact information
Loop Energy Investor Inquiries:
Natalie Arseneau | Tel: +1 604.222.3400 Ext. 418 | investors@loopenergy.com
Loop Energy Business Inquiries:
George Rubin | Tel: +1.604.828.8185 | grubin@loopenergy.com
Loop Energy Media Inquiries:
Ethan Hugh | Tel: +1 604.306.4277| ethan.hugh@loopenergy.com
Lucas Schmidt | Tel: +1.778.791.8756 | lucas.schmidt@loopenergy.com
Fraunhofer ISE Inquiries:
Dr. Tom Smolinka | Tel: +49.761.4588.5212 | tom.smolinka@ise.fraunhofer.de
Diana Bribach | Tel: +49.761.4588.2804 | diana.bribach@ise.fraunhofer.de
Fraunhofer USA Inquiries:
Elliott Sprehe | Tel: +734.927.3984 | esprehe@fraunhofer.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
